Susan Nichols is the CEO of Propel Biosciences and a recognized C-suite leader in cell and gene therapy, bringing deep experience as a CEO, CBO, and CCO-level operator specializing in growth-stage commercialization and organizational build-out. With more than two decades across drug development, CDMO services, and advanced therapy manufacturing, she has led high-performing teams in both emerging biotech ventures and global organizations including Invetech/Danaher, Thermo Fisher/ASI, Hitachi Chemical, and Roche Diagnostics.

At Propel Biosciences, Susan leads a commercialization acceleration firm that helps biotech and advanced therapy organizations translate complex science into clear market positioning, early revenue traction, and scalable commercial infrastructure. She works hands-on with leadership teams to define differentiated narratives, build disciplined go-to-market models, and operationalize growth with speed and precision.  Propel provides outsourced business development and sales support for every stage of growth.

A former CEO in the gene-modified cell therapy field, Susan is known for her ability to synthesize complex scientific landscapes into clear, forward-looking strategies that help executive teams navigate critical inflection points, anticipate market shifts, and position technologies for long-term impact. Recognized for her thought leadership in advanced therapies and biomanufacturing, she speaks globally on commercialization models and leadership in high-growth scientific organizations.